2026年9月18日 上午9:51 UTC / 路透社
REUTERS/Dado Ruvic/Illustration
涉及企业
礼来公司
诺和诺德公司
辉瑞制药有限公司
9月18日（路透社）——据Semafor援引美国政府计划报道，唐纳德·特朗普政府将于周五宣布，全美50个州的医疗补助计划（Medicaid）都将对特定药品实施最惠国定价。
Semafor称，特朗普总统将在椭圆形办公室接待南达科他州、密西西比州和阿肯色州的州长，“宣传降低药品价格方面的工作成果”。
不实信息监控简报
该简报将汇总国际不实信息叙事，每一期都包含“真实还是虚假？”问答环节。点击此处注册
路透社无法立即核实这一报道。
白宫和美国卫生与公众服务部并未立即回应路透社的置评请求。
美国的处方药支出高于其他任何国家，通常几乎是其他发达国家的三倍。特朗普曾多次表示，他希望缩小这一差距。
自去年以来，他的政府已与包括辉瑞、礼来和诺和诺德在内的17家全球大型制药商签署了协议。
这些企业同意提供更低的价格，与其他发达国家的支付价格相当——这被称为“最惠国定价”。
由州和联邦政府共同资助的医疗补助计划，已经根据现行法律要求从制药商那里获得了大幅折扣。该计划覆盖的大多数低收入美国人几乎无需自付处方药费用。
上个月，该政府宣布与国际制药公司和一些小型生物技术公司达成新一轮药品定价协议。
路透社 阿努莎·沙阿和斯里帕尔娜·罗伊 班加罗尔报道；托比·乔普拉和乔伊吉特·达斯 编辑
US plans Medicaid most-favored-nation pricing for some drugs in all states, Semafor reports
2026-09-18 9:51 AM UTC / Reuters
U.S. dollar banknote and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration
Companies
Eli Lilly and Company
Novo Nordisk A/S
Pfizer Inc.
Sept 18 (Reuters) – The Donald Trump administration is set to announce on Friday that all 50 states would see most-favored-nation pricing for certain drugs in Medicaid programs, Semafor reported, citing administration plans.
President Trump will host the governors of South Dakota, Mississippi and Arkansas in the Oval Office “to tout work on lower drug prices,” Semafor said.
The Misinformation Monitor newsletter rounds up international misinformation narratives, with a “Real or Fake?” quiz in every edition. Sign up here.
Reuters could not immediately verify the report.
The White House and US Department of Health and Human Services did not immediately respond to a Reuters request for comment.
The US pays more for prescription drugs than any other country, often nearly thrice as much as other developed nations. Trump has repeatedly said he wants to narrow this gap.
His administration signed deals with 17 of the largest global drugmakers, including Pfizer, Eli Lilly and Novo Nordisk, starting last year.
The companies agreed to offer lower prices, comparable to what is paid in other developed countries — referred to as “most-favored-nation” pricing.
Medicaid, funded jointly by state and federal governments, already draws steep discounts from drugmakers, mandated by existing law. Most people covered by the health program for low-income Americans pay little out of pocket for prescriptions.
Last month, the administration announced a new round of drug-pricing agreements with international pharmaceutical companies and some smaller biotechs.
Reporting by Anusha Shah and Sriparna Roy in Bengaluru; Editing by Toby Chopra and Joyjeet Das
发表回复